Evidence-based weight loss interventions: Individualized treatment options to maximize patient outcomes

被引:86
作者
Bray, George A. [1 ]
Ryan, Donna H. [1 ]
机构
[1] Louisiana State Univ, Pennington Biomed Res Ctr, Baton Rouge, LA 70808 USA
关键词
bariatric; metabolic surgery; comprehensive lifestyle programme; diet; medications for obesity; personalized obesity management; LIFE-STYLE INTERVENTION; LOW-CARBOHYDRATE DIET; BARIATRIC SURGERY; CARDIOVASCULAR-DISEASE; CONTROLLED-TRIAL; BODY-WEIGHT; LOW-FAT; OBESITY; PROGRAM; RISK;
D O I
10.1111/dom.14200
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Against the backdrop of obesity as a major public health problem, we examined three questions: How much weight loss is needed to benefit patients with obesity? How well do current therapies do in producing weight loss? What strategies can be used to improve patient outcomes using evidence-based studies. This paper reviews literature on the outcomes of lifestyle, diet, medications and surgical treatments for obesity using literature searches for obesity treatments. Current treatments, including lifestyle, diet and exercise, produce a weight loss of 5% to 7% on average. Despite continued attempts to identify superior dietary approaches, most careful comparisons find that low carbohydrate diets are not significantly better than low fat diets for weight loss. The four medications currently approved by the US Food and Drug Administration for long-term management of obesity are not as effective as surgery, adding about 5% on average to lifestyle approaches to weight loss. Two new medications that are under investigation, semaglutide and tirzepatide, significantly improve on this. For all treatments for weight loss, including lifestyle, medications and surgery, there is enormous variability in the amount of weight lost. Examination of this literature has yielded evidence supporting baseline and process predictors, but the effect sizes associated with these predictors are small and there are no prospective studies showing that a personalized approach based on genotype or phenotype will yield uniform success. Because obesity is a chronic disease it requires a 'continuous treatment model' across the lifespan.
引用
收藏
页码:50 / 62
页数:13
相关论文
共 88 条
[1]   Pediatric Obesity: Influence on Drug Dosing and Therapeutics [J].
Ameer, Barbara ;
Weintraub, Michael A. .
JOURNAL OF CLINICAL PHARMACOLOGY, 2018, 58 (10) :S94-S107
[2]  
[Anonymous], 1863, Letter on Corpulence, Addressed to the Public
[3]   Long-Term Weight Loss With Metformin or Lifestyle Intervention in the Diabetes Prevention Program Outcomes Study [J].
Apolzan, John W. ;
Venditti, Elizabeth M. ;
Edelstein, Sharon L. ;
Knowler, William C. ;
Dabelea, Dana ;
Boyko, Edward J. ;
Pi-Sunyer, Xavier ;
Kalyani, Rita R. ;
Franks, Paul W. ;
Srikanthan, Preethi ;
Gadde, Kishore M. .
ANNALS OF INTERNAL MEDICINE, 2019, 170 (10) :682-+
[4]   Pharmacological Management of Obesity: An Endocrine Society Clinical Practice Guideline [J].
Apovian, Caroline M ;
Aronne, Louis J. ;
Bessesen, Daniel H. ;
McDonnell, Marie E. ;
Murad, M. Hassan ;
Pagotto, Uberto ;
Ryan, Donna H. ;
Still, Christopher D. .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2015, 100 (02) :342-362
[5]   Comparative Effectiveness and Safety of Bariatric Procedures for Weight Loss A PCORnet Cohort Study [J].
Arterburn, David ;
Wellman, Robert ;
Emiliano, Ana ;
Smith, Steven R. ;
Odegaard, Andrew O. ;
Murali, Sameer ;
Williams, Neely ;
Coleman, Karen J. ;
Courcoulas, Anita ;
Coley, R. Yates ;
Anau, Jane ;
Pardee, Roy ;
Toh, Sengwee ;
Janning, Cheri ;
Cook, Andrea ;
Sturtevant, Jessica ;
Horgan, Casie ;
McTigue, Kathleen M. .
ANNALS OF INTERNAL MEDICINE, 2018, 169 (11) :741-+
[6]   Comparison among criteria to define successful weight-loss maintainers and regainers in the Action for Health in Diabetes (Look AHEAD) and Diabetes Prevention Program trials [J].
Berger, Samantha E. ;
Huggins, Gordon S. ;
McCaffery, Jeanne M. ;
Lichtenstein, Alice H. .
AMERICAN JOURNAL OF CLINICAL NUTRITION, 2017, 106 (06) :1337-1346
[7]   Human postprandial responses to food and potential for precision nutrition [J].
Berry, Sarah E. ;
Valdes, Ana M. ;
Drew, David A. ;
Asnicar, Francesco ;
Mazidi, Mohsen ;
Wolf, Jonathan ;
Capdevila, Joan ;
Hadjigeorgiou, George ;
Davies, Richard ;
Al Khatib, Haya ;
Bonnett, Christopher ;
Ganesh, Sajaysurya ;
Bakker, Elco ;
Hart, Deborah ;
Mangino, Massimo ;
Merino, Jordi ;
Linenberg, Inbar ;
Wyatt, Patrick ;
Ordovas, Jose M. ;
Gardner, Christopher D. ;
Delahanty, Linda M. ;
Chan, Andrew T. ;
Segata, Nicola ;
Franks, Paul W. ;
Spector, Tim D. .
NATURE MEDICINE, 2020, 26 (06) :964-+
[8]   Effects of once-weekly semaglutide on appetite, energy intake, control of eating, food preference and body weight in subjects with obesity [J].
Blundell, John ;
Finlayson, Graham ;
Axelsen, Mads ;
Flint, Anne ;
Gibbons, Catherine ;
Kvist, Trine ;
Hjerpsted, Julie B. .
DIABETES OBESITY & METABOLISM, 2017, 19 (09) :1242-1251
[9]   Look AHEAD (Action for Health in Diabetes): design and methods for a clinical trial of weight loss for the prevention of cardiovascular disease in type 2 diabetes [J].
Brancati, F ;
Charleston, J ;
Cheskin, L ;
Clark, J ;
DiGregorio-Celnik, D ;
Friedman-Donze, L ;
Rubin, R ;
Stewart, K ;
Bray, GA ;
DeLee, DG ;
Boss, KR ;
Greenway, FL ;
Lovejoy, JC ;
Ryan, DH ;
Williamson, DA ;
West, DS ;
DiLillo, V ;
Raczynski, JM ;
Lewis, CE ;
Oberman, A ;
Thomas, S ;
Nathan, DM ;
Horton, ES ;
Turgeon, H ;
Jackson, SD ;
Blackburn, GL ;
Delahanty, L ;
Steiner, B ;
Cagliero, E ;
Mantzoros, C ;
Hill, JO ;
Phillipp, J ;
Hamman, RF ;
Schwartz, R ;
Regensteiner, J ;
Van Dorsten, B ;
McDermott, MT ;
Dills, DG ;
Foreyt, JP ;
Reeves, RS ;
Pownell, HJ ;
Balasubramanyam, A ;
Jones, PH ;
Saad, MF ;
Jinagouda, S ;
Chiu, K ;
Morales, L ;
Ghazarian, S ;
Navarrete, G ;
Iqbal, N .
CONTROLLED CLINICAL TRIALS, 2003, 24 (05) :610-628
[10]   Obesity: a chronic relapsing progressive disease process. A position statement of the World Obesity Federation [J].
Bray, G. A. ;
Kim, K. K. ;
Wilding, J. P. H. .
OBESITY REVIEWS, 2017, 18 (07) :715-723